Outpatient Therapy

  • Brian E. Jaski
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 228)


Once a patient has a diagnosis of heart failure including assessments of left ventricular function and etiology, it is important to tailor therapies that will improve a patient’s quality of life and survival. Effective outpatient management can reduce the need for hospitalization and, in turn, save health care resources. This chapter serves as a guide to patient treatment and counseling, paying special attention to multicenter trials and pharmacologic treatments.


Heart Failure Heart Failure Patient Angiotensin Converting Enzyme Inhibitor Hypertrophic Cardiomyopathy Isosorbide Dinitrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Franciosa JA, Jordan RA, Wilen MM, Leddy CL. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation. 1984; 70:63–68.PubMedCrossRefGoogle Scholar
  2. 2.
    Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N.Engl.J.Med. 1988; 319:80–86.PubMedCrossRefGoogle Scholar
  3. 3.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N.Engl.J.Med. 1992; 327:685–691.CrossRefGoogle Scholar
  4. 4.
    Coats AJ, Exercise training for heart failure: coming of age. Circulation. 1999; 99:1138–1140.PubMedCrossRefGoogle Scholar
  5. 5.
    Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999; 99:1173–1182.PubMedCrossRefGoogle Scholar
  6. 6.
    Hare DL, Ryan TM, Selig SE, Pellizzer AM, Wrigley TV, Krum H. Resistance exercise training increases muscle strength, endurance, and blood flow in patients with chronic heart failure. Am.J. Cardiol. 1999; 83:1674–1677, A7.PubMedCrossRefGoogle Scholar
  7. 7.
    Lang RM, Borow KM, Neumann A, Feldman T. Adverse cardiac effects of acute alcohol ingestion in young adults. Ann.Intern.Med. 1985; 102:742–747.PubMedGoogle Scholar
  8. 8.
    Konstam MA, Dracup K, Baker DW. Heart failure: Evaluation and care of patients with left-ventricular systolic dysfunction. 1994; 11, US Department of Health and Human Services.Google Scholar
  9. 9.
    Krumholz HM, Butler J, Miller J, Vaccarino V, Williams CS, Mendes DLC, Seeman TE, Kasl SV, Berkman LF. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation. 1998; 97:958–964.PubMedCrossRefGoogle Scholar
  10. 10.
    Schiller E, Baker J. Return to work after a myocardial infarction: evaluation of planned rehabilitation and of a predictive rating scale. Med.J.Aust. 1976; 1:859–862.PubMedGoogle Scholar
  11. 11.
    Bar FW, Hoppener P, Diederiks J, Voken H, Bekkers J, Hoofd W. A Appels, HJ Wellins, Cardiac rehabilitation contributes to the restoration of leisure and social activities after myocardial infarction. J. Cardiopulm. Rehabil. 1992; 12:117–125.CrossRefGoogle Scholar
  12. 12.
    Gutgesell HP, Gessner IH, Vetter VL, Yabek SM, Norton JBJ. Recreational and occupational recommendations for young patients with heart disease. A statement for physicians by the committee on congenital cardiac defects of the council on cardiovascular disease in the young, American Heart Association. Circulation. 1986; 74:1195A–1198A.PubMedCrossRefGoogle Scholar
  13. 13.
    Fletcher G, Fernandez V. Screening and Evaluation of Patients for Exercise Training. In: Balady GJ, Pina I, editors. Exercise and heart failure. Armonk: Futura Publishing Company, Inc., 1997; 311–320.Google Scholar
  14. 14.
    Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am.Heart J. 1997; 133:703–712.PubMedCrossRefGoogle Scholar
  15. 15.
    Kostis JB, Davis BR, Cutler J, Grimm RH, Jr., Berge KG, Cohen JD, Lacy CR, Perry HM, Jr., Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278:212–216.PubMedCrossRefGoogle Scholar
  16. 16.
    Kjekshus J, Pedersen TH. Lowering of cholesterol with simvastatin may prevent development of heart failure in patients with coronary heart disease. Circulation. 1995; 282A.Google Scholar
  17. 17.
    Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SCJ, Alexander CM, Londhe A, Lulla A, Simpson RJJ. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am.J.Cardiol. 1999; 83:1303–1307.PubMedCrossRefGoogle Scholar
  18. 18.
    Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997; 96:4065–4082.PubMedCrossRefGoogle Scholar
  19. 19.
    Katz AM. The cardiomyopathy of overload: an unnatural growth response. Eur.Heart J. 1995; 16 (Suppl O):110–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Packer M. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am. J. Cardiol. 1999; 83:1A–38A.CrossRefGoogle Scholar
  21. 21.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N.Engl.J.Med. 1999; 341:709–717.PubMedCrossRefGoogle Scholar
  22. 22.
    Brater DC. Diuretic therapy. N.Engl.J. Med. 1998; 339:387–395.PubMedCrossRefGoogle Scholar
  23. 23.
    Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97:1411–1420.PubMedCrossRefGoogle Scholar
  24. 24.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293–302.CrossRefGoogle Scholar
  25. 25.
    Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100:2312–2318.PubMedCrossRefGoogle Scholar
  26. 26.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N.Engl.J.Med. 1992; 327:669–677.PubMedCrossRefGoogle Scholar
  27. 27.
    Gruppo Italiano per lo Studio della Sopravvivenza neH’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994; 343:1115–1122.Google Scholar
  28. 28.
    ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995; 345:669–685.CrossRefGoogle Scholar
  29. 29.
    M. St. John Sutton, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994; 89:68–75.CrossRefGoogle Scholar
  30. 30.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N.Engl.J.Med. 1991; 325:303–310.PubMedCrossRefGoogle Scholar
  31. 31.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N.Engl.J.Med. 1991; 325:293–302.CrossRefGoogle Scholar
  32. 32.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N.Engl.J.Med. 1987; 316:1429–1435.CrossRefGoogle Scholar
  33. 33.
    Brunner-La Rocca HP, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-ll antagonism. J. Am.Coll.Cardiol. 1999; 33:1163–1173.CrossRefGoogle Scholar
  34. 34.
    Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997; 349:747–752.PubMedCrossRefGoogle Scholar
  35. 35.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation. 1999; 99:2658–2664.PubMedCrossRefGoogle Scholar
  36. 36.
    Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999; 99: 990–992.PubMedCrossRefGoogle Scholar
  37. 37.
    Levine TB, Levine AB, Keteyian SJ, Narins B, Lesch M. Reverse remodeling in heart failure with intensification of vasodilator therapy. Clin.Cardiol. 1997; 20:697–702.PubMedCrossRefGoogle Scholar
  38. 38.
    Cusick DA, Pfeifer PB, Quigg RJ. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Am. J. Cardiol. 1998; 82:1060–1065.PubMedCrossRefGoogle Scholar
  39. 39.
    Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N.Engl.J.Med. 1991; 325:303–310.PubMedCrossRefGoogle Scholar
  40. 40.
    Elkayam U, Johnson JV, Shotan A, Bokhari S, Solodky A, Canetti M, Wani OR, Karaalp IS. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation. 1999; 99:2652–2657.PubMedCrossRefGoogle Scholar
  41. 41.
    Haude M, Steffen W, Erbel R, Meyer J. Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure. Int.J.Cardiol. 1990; 27:351–359.PubMedCrossRefGoogle Scholar
  42. 42.
    Fifer MA, Colucci WS, Lorell BH, Jaski BE, Barry WH. Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside. J. Am. Coll. Cardiol. 1985; 5:731–737.PubMedCrossRefGoogle Scholar
  43. 43.
    Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation. 1984; 69:740–747.PubMedCrossRefGoogle Scholar
  44. 44.
    Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991; 83:52–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Elkayam U. Calcium channel blockers in heart failure. Cardiology. 1998; 89 (Suppl 1):38–46.PubMedCrossRefGoogle Scholar
  46. 46.
    Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N.Engl.J.Med. 1996; 335:1107–1114.PubMedCrossRefGoogle Scholar
  47. 47.
    O’Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am.J. Cardiol. 1998; 82:881–887.PubMedCrossRefGoogle Scholar
  48. 48.
    Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997; 96:856–863.PubMedCrossRefGoogle Scholar
  49. 49.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N.Engl.J.Med. 1997; 336:525–533.CrossRefGoogle Scholar
  50. 50.
    Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989; 80: 65–77.PubMedCrossRefGoogle Scholar
  51. 51.
    Young JB, Gheorghiade M, Uretsky BF, Patterson JH, Adams KFJ. Superiority of “triple” drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J. Am.Coll.Cardiol. 1998; 32:686–692.PubMedCrossRefGoogle Scholar
  52. 52.
    Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342:1441–1446.PubMedCrossRefGoogle Scholar
  53. 53.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001–2007.CrossRefGoogle Scholar
  54. 54.
    The CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353:9–13.CrossRefGoogle Scholar
  55. 55.
    Frishman WH. Carvedilol. N.Engl.J Med. 1998; 339:1759–1765.PubMedCrossRefGoogle Scholar
  56. 56.
    Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996; 94:2817–2825.PubMedCrossRefGoogle Scholar
  57. 57.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N.Engl.J.Med. 1996; 334:1349–1355.PubMedCrossRefGoogle Scholar
  58. 58.
    Di Lenarda A, Sabbadini F, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, Gregori D, Ciani F, Muzzi A, Klugmann S, Camerini F. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J. Am.Coll.Cardiol. 1999; 33:1926–1934.PubMedCrossRefGoogle Scholar
  59. 59.
    Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, Eng C. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999; 99:2645–2651.PubMedCrossRefGoogle Scholar
  60. 60.
    Hjalmarson A, Kneider M, Waagstein F. The role of beta-blockers in left ventricular dysfunction and heart failure. Drugs. 1997; 54:501–510.PubMedCrossRefGoogle Scholar
  61. 61.
    Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997; 349:375–380.CrossRefGoogle Scholar
  62. 62.
    Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am. J. Cardiol. 1999; 83:1201–1205.PubMedCrossRefGoogle Scholar
  63. 63.
    Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J. Am. Coll.Cardiol. 1999; 33:924–931.PubMedCrossRefGoogle Scholar
  64. 64.
    Senni M, Redfield MM. Congestive heart failure in elderly patients. Mayo Clin.Proc. 1997; 72:453–460.PubMedCrossRefGoogle Scholar
  65. 65.
    Ruzumna P, Gheorghiade M, Bonow RO. Mechanisms and management of heart failure due to diastolic dysfunction. Curr.Opin.Cardiol. 1996; 11:269–275.PubMedCrossRefGoogle Scholar
  66. 66.
    Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population- based cohort. J. Am.Coll.Cardiol. 1999; 33:1948–1955.PubMedCrossRefGoogle Scholar
  67. 67.
    Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J.Am.Coll.Cardiol. 1997; 30:8–18.PubMedCrossRefGoogle Scholar
  68. 68.
    Neaton JD, Grimm RHJ, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993; 270:713–724.PubMedCrossRefGoogle Scholar
  69. 69.
    Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N.Engl.J.Med. 1997; 336:775–785.PubMedCrossRefGoogle Scholar
  70. 70.
    Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J.Am.Coll.Cardiol. 1997; 29:435–441.PubMedCrossRefGoogle Scholar
  71. 71.
    Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N.Engl.J.Med. 1997; 336:775–785.PubMedCrossRefGoogle Scholar
  72. 72.
    Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug- refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999; 99:2927–2933.PubMedCrossRefGoogle Scholar
  73. 73.
    Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J. Am.Coll.Cardiol. 1999; 34:191–196.PubMedCrossRefGoogle Scholar
  74. 74.
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346:211–214.PubMedCrossRefGoogle Scholar
  75. 75.
    Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J.Am.Coll.Cardiol. 1998; 31:252–258.PubMedCrossRefGoogle Scholar
  76. 76.
    Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, Valentino M, Brugada P. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J.Am.Coll.Cardiol. 1998; 31:1081–1085.PubMedCrossRefGoogle Scholar
  77. 77.
    Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997; 96:2455–2461.PubMedCrossRefGoogle Scholar
  78. 78.
    Waktare JE, Camm AJ. Acute treatment of atrial fibrillation: why and when to maintain sinus rhythm. Am.J.Cardiol. 1998; 8:3C–15C.Google Scholar
  79. 79.
    Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N.Engl.J Med. 1999; 341:910–911.PubMedCrossRefGoogle Scholar
  80. 80.
    Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am.J.Cardiol. 1989; 63:1065–1068.PubMedCrossRefGoogle Scholar
  81. 81.
    Brignole M, Menozzi C, Gianfranchi L, Musso G, Mureddu R, Bottoni N and Lolli G. Assessment of atrioventricular junction ablation and WIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation. 1998; 98:953–960.PubMedCrossRefGoogle Scholar
  82. 82.
    Goodman, Gilman. The pharmacological basis of therapeutics. 8 ed. Philadelphia: McGraw Hill, 1990; 866–869.Google Scholar
  83. 83.
    Kaye DM, Dart AM, Jennings GL, Esler MD. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J. Am.Coll.Cardiol. 1999; 33:1553–1559.PubMedCrossRefGoogle Scholar
  84. 84.
    Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, Gent M, Janse MJ, Dorian P, Frangin G. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation. 1999; 99:2268–2275.PubMedCrossRefGoogle Scholar
  85. 85.
    The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N.Engl.J.Med. 1997; 337:1576–1583.CrossRefGoogle Scholar
  86. 86.
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N.Engl.J.Med. 1996; 335:1933–1940.PubMedCrossRefGoogle Scholar
  87. 87.
    Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J.Am.Coll.Cardiol. 1998; 31:749–753.PubMedCrossRefGoogle Scholar
  88. 88.
    Rich MW, Freedland KE. Effect of DRGs on three-month readmission rate of geriatric patients with congestive heart failure. Am.J.Public Health 1988; 78:680–682.PubMedCrossRefGoogle Scholar
  89. 89.
    Shah NB, Der E, Ruggerio C, Heidenreich PA, Massie BM. Prevention of hospitalizations for heart failure with an interactive home monitoring program. Am.Heart J. 1998; 135:373–378.PubMedCrossRefGoogle Scholar
  90. 90.
    Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J.Am.Coll.Cardiol. 1997; 30:725–732.PubMedCrossRefGoogle Scholar
  91. 91.
    Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LHG, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991; 83:778–786.PubMedCrossRefGoogle Scholar
  92. 92.
    Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw U, Kargl D, Chaitman BR. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ishemic and dilated cardiomyopathy. J.Am.Coll.Cardiol. 1996; 27:345–352.PubMedCrossRefGoogle Scholar
  93. 93.
    Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349:1050–1053.PubMedCrossRefGoogle Scholar
  94. 94.
    Fletcher G, Balady G, Froelicher VF et al. Exercise Standards. A statement for healthcare professionals from the American Heart Association.Circulation. 1995; 91:580.PubMedCrossRefGoogle Scholar
  95. 95.
    Kobashigawa JA. Mycophenolate mofetil in cardiac transplantation. Curr.Opin.Cardiol. 1998; 13:117–121.PubMedCrossRefGoogle Scholar
  96. 96.
    Mentzer RMJ, Jahania MS, Lasley RD. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation. 1998; 65:109–113.PubMedCrossRefGoogle Scholar
  97. 97.
    Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ. The registry of the international society for heart and lung transplantation: fourteenth official report-1997. J.Heart Lung Transplant. 1997; 16:691–712.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Brian E. Jaski
    • 1
    • 2
  1. 1.Advanced Heart Failure and Cardiac Transplant ProgramsSharp Memorial HospitalSan DiegoUSA
  2. 2.San Diego School of MedicineUniversity of CaliforniaUSA

Personalised recommendations